Northern Biologics, Inc. logo

Northern Biologics, Inc.

Northern Biologics, is developing a portfolio of antibody-based therapeutics for the treatment of human diseases in oncology and fibrosis. It also focus on developing novel functional modulators of key signalling pathways in cancer and fibrosis.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://northernbiologics.com
Disease Focus
STOCK CODENon Listed
Address
101 College Street TMDT 11-301, M5G 1L7
Toronto
Canada
Email
Contact Number

Northern Biologics, is developing a portfolio of antibody-based therapeutics for the treatment of human diseases in oncology and fibrosis. It also focus on developing novel functional modulators of key signalling pathways in cancer and fibrosis.

Northern Biologics has in-licensed intellectual property from both University of Toronto and UHN including drug leads and a novel antibody generation platform for development of antibody-based therapeutics for both oncology and fibrosis.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/northern-biologics” connections=”true” suffix=””]

In Apr 2015, Northern Biologics signed agreement with Celgene Corporation, under the terms Celgen provided $30 Mn in upfront payments to discover and develop first-in-class therapeutic antibodies, and an option to acquire Northern Biologics.

In Dec 2014, Northern Biologics, complete $10 Mn series A financing from Versant Ventures.